Compare VAL & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | LIVN |
|---|---|---|
| Founded | 1975 | 1987 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | N/A | 1993 |
| Metric | VAL | LIVN |
|---|---|---|
| Price | $50.30 | $61.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $54.80 | ★ $65.00 |
| AVG Volume (30 Days) | ★ 1.1M | 563.7K |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.61 | N/A |
| Revenue | ★ $2,416,000,000.00 | $1,348,962,000.00 |
| Revenue This Year | N/A | $12.25 |
| Revenue Next Year | N/A | $6.75 |
| P/E Ratio | $9.03 | ★ N/A |
| Revenue Growth | 6.81 | ★ 8.63 |
| 52 Week Low | $27.15 | $32.48 |
| 52 Week High | $61.70 | $65.57 |
| Indicator | VAL | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 50.58 |
| Support Level | $49.00 | $61.79 |
| Resistance Level | $51.34 | $63.58 |
| Average True Range (ATR) | 1.81 | 1.26 |
| MACD | -0.28 | -0.47 |
| Stochastic Oscillator | 20.56 | 4.05 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.